SLC5A2 and chronic kidney disease: On the other hand, sodium-glucose co-transporter 2 (SGLT2) inhibitors (SGLTis) have proven efficacy on the progression of CKD in patients with IgAN: in the IgAN subgroup analyses of DAPA-CKD and EMPA-KIDNEY a reduction of CKD progression has been shown [14, 15].